To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with the Centre for Disease Control in the US on their use of Evusheld as a pre-exposure prophylaxis to prevent Covid-19 in people who are moderately to severely immunocompromised.

The Antivirals and Therapeutics Taskforce has regular engagement with international partners to share learning on the use, deployment and evaluation of therapeutics and antivirals, including Evusheld. The Taskforce recently met with counterparts from the United States of America and discussed the recent change to the Food and Drug Administration’s treatment guidelines, which recommends physicians advise individuals to have appropriate alternate treatment plans in place, should emerging COVID-19 variants be resistant to Evusheld.

We continue monitoring whether and how other countries are using pre-exposure prophylactic treatments in people who are moderately to severely immunocompromised.